FindTrial
Sign In

oxaliplatin-based chemotherapy

DRUG3 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Hospices Civils de Lyon, Fox Chase Cancer Center

Conditions

Metastatic Colorectal Cancer (CRC)Neuroendocrine TumorsNeurotoxicityOxaliplatin Induced Peripheral Neuropathy in Cancer PatientsPeripheral Neuropathy Due to Chemotherapy

Early Phase 1

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RecruitingNCT07167446
Fox Chase Cancer CenterMetastatic Colorectal Cancer (CRC), Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Peripheral Neuropathy Due to Chemotherapy
Start: 2025-10-14End: 2028-09-07Target: 30Updated: 2025-10-22

Phase 3

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
CompletedNCT02486198
Tianjin Medical University Cancer Institute and HospitalNeurotoxicity
Start: 2015-05-05End: 2018-02-02Updated: 2018-02-05

Unknown Phase

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
CompletedNCT03217097
Hospices Civils de LyonNeuroendocrine Tumors
Start: 2018-10-16End: 2022-04-25Updated: 2025-11-21

Related Papers

Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O <sup>6</sup> -Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
Journal of Clinical Oncology2024-11-2511 citations
Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.
2021-10-294 citations
Survival and safety of monosialotetrahexosylganglioside in GI cancer patients with oxaliplatin-induced peripheral neurotoxicity-result from TJMUCH-GI-001 trial.
Journal of Clinical Oncology2019-05-20
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
2019-02-1429 citations
Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).
Journal of Clinical Oncology2018-05-201 citations